Patent Baristas

As noted on Law.com, people came out in droves to the U.S. Court of Appeals for the Federal Circuit on Tuesday to listen to arguments for a case on claim interpretation.  In Phillips v. AWH Corp., 363 F.3d 1207 (Fed. Cir. 2004), the claimed term “baffle” was limited to baffles that were at an angle […]

Barr Pharmaceuticals Inc. sued the U.S. Food and Drug Administration in the U.S. District Court for the District of Columbia, seeking exclusive rights to sell a generic version of Sanofi-Aventis’ Allegra-D allergy drug. In the suit, Barr is challenging the FDA’s policy of awarding generic exclusivity on a patent-by-patent basis rather than solely to the […]

Law.com reported that the California Supreme Court agreed to review an appellate decision in which a $500 million judgment for City of Hope National Medical Center against Genentech, including $200 million in punitive damages. Genentech negotiated a license agreement to develop and market human insulin and human growth hormone based on research at City of […]

The U.S. of Appeals for the Federal Circuit invalidated U.S. Patent No. 5,994,329 (the ‘329 patent), covering the  osteoporosis drug Fosamax made by Merck & Co.  The court reversed and vacated an earlier ruling by the U.S. District Court in Delaware that had upheld the validity of the patent. The patent is listed in the […]

Forbes ran an article that Credit Suisse First Boston expects Pfizer to hold onto its Lipitor patent until March 2010, which is "earlier than the pre-litigation expectation of December 2011, but later than some estimates for 2006." It doesn’t expect a decision for the Lipitor patent trial before the summer of 2005. This would reduce […]

The Boston Globe reported that Genzyme Corp. sued Transkaryotic Therapies Inc. in the District Court of Tel Aviv, claiming that their method of purifying a treatment for Gaucher’s disease infringed on Genzyme’s Israeli patent No. 100,715, which covers certain cell culture processes involved in the manufacture of glucocerebrosidase.  TKT is conducting a clinical trial in […]

Reuters reported that Teva Pharmaceuticals Industries Ltd. lost its bid to keep 180 days of exclusivity for its generic version of Pfizer Inc.’s popular Zoloft antidepressant. The U.S. Court of Appeals for the Federal Circuit, in Teva Pharmaceuticals, Inc v. Pfizer Inc., 04-1186, rejected Teva’s bid to overturn a lower court ruling over whether the […]

Mergen Limited announced it has resolved its patent infringement litigation case with Oxford Gene Technology.  Under the terms of the settlement, Mergen has obtained a license from OGT for its expression chips in the U.S., Europe and Japan.  This license allows Mergen to manufacture and sell microarrays, e.g., Mergen’s ExpressChip(TM) DNA microarray system for high-throughput, […]